Evidence map›Paper›PMID 34071809›Full record

ArticleMolecules (Basel, Switzerland)2021

In Vitro Evaluation of Antiproliferative Properties of Novel Organotin(IV) Carboxylate Compounds with Propanoic Acid Derivatives on a Panel of Human Cancer Cell Lines.

Nebojša Đ Pantelić, Bojan Božić, Bojana B Zmejkovski, Nebojša R Banjac, Biljana Dojčinović, Ludger A Wessjohann, Goran N Kaluđerović

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nebojša Đ PantelićDepartment of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Eberhard-Leibnitz-Straße 2, DE-06217 Merseburg, Germany.ORCID 0000-0003-1843-9890
Bojan BožićFaculty of Biology, Institute of Physiology and Biochemistry "Ivan Djaja", University of Belgrade, Studentski trg 16, 11000 Belgrade, Serbia.ORCID 0000-0001-9910-2741
Bojana B ZmejkovskiDepartment of Chemistry, Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Studentski trg 14, 11000 Belgrade, Serbia.
Nebojša R BanjacDepartment of Chemistry and Biochemistry, Faculty of Agriculture, University of Belgrade, Nemanjina 6, 11080 Zemun, Belgrade, Serbia.
Biljana DojčinovićDepartment of Chemistry, Institute of Chemistry, Technology and Metallurgy, University of Belgrade, Studentski trg 14, 11000 Belgrade, Serbia.
Ludger A WessjohannDepartment of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry, Weinberg 3, 06120 Halle (Saale), Germany.
Goran N KaluđerovićDepartment of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Eberhard-Leibnitz-Straße 2, DE-06217 Merseburg, Germany.ORCID 0000-0001-5168-1000
University of Belgrade · RSMerseburg University of Applied Sciences · DELeibniz Institute of Plant Biochemistry · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The synthesis of novel triphenyltin(IV) compounds, Ph

Indexed as

AnimalsCell Line, TumorDrug Screening Assays, AntitumorFemaleGentian VioletHeLa CellsHT29 CellsHumansInhibitory Concentration 50In Vitro TechniquesLigandsMass SpectrometryMCF-7 CellsMetalsMiceNeoplasmsGentian VioletLigandsMetalsOrganotin CompoundsReactive Nitrogen SpeciesReactive Oxygen Speciesapoptosisbreast cancercytotoxicityICP-MStriphenyltin(IV)

Identifiers

PMID34071809
PMCPMC8198038
OpenAlexW3165290153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.